Barclays PLC Akebia Therapeutics, Inc. Call Options Transaction History

Barclays PLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2020 May 13, 2020	SELL	$4.1 - $10.24 $1,603 - $4,003	-391 Reduced 24.58%	1,200 $9,000
Q4 2019 Feb 10, 2020	SELL	$3.16 - $6.73 $13,904 - $29,612	-4,400 Reduced 73.44%	1,591 $10,000
Q3 2019 Nov 14, 2019	BUY	$3.55 - $5.4 $1,420 - $2,160	400 Added 7.15%	5,991 $23,000
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $10,250 - $20,125	2,500 Added 80.88%	5,591 $27,000
Q1 2019 May 15, 2019	SELL	$5.41 - $8.73 $1,536 - $2,479	-284 Reduced 8.41%	3,091 $25,000
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $18,191 - $30,881	3,375 New	3,375 $19,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $338M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.